Clinical Trial Update: A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment [Phase 1]

View source ↗

Summary

Phase I study of ChiLob 7/4, a chimeric anti-CD40 monoclonal antibody, in patients with advanced cancers refractory to conventional treatment; the trial status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Cancer
• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• ChiLob 7/4 (Chimeric anti-CD40 monoclonal antibody)

Snippet

Sponsor: Cancer Research UK | Conditions: Cancer, Neoplasms | Phase 1 | Status: COMPLETED